SynthesisThe Lancet. Global health2026
Strategies to reduce antimicrobial resistance in newborns in low-income and middle-income countries: a systematic review and meta-analysis.
Synthesis in The Lancet. Global health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevention and Treatment of Neonatal Infections in Facility and Community Settings of Low- and Middle-Income Countries: A Descriptive Review.Neonatology · 2025Pooled it
- Reflections on a global partnership for perinatal quality improvement in Rwanda.BMJ paediatrics open · 2026Review
- Article
- Costs and cost-effectiveness of an infection prevention bundle to reduce neonatal sepsis and mortality in Zambia: The Sepsis Prevention in Neonates in Zambia (SPINZ) trial.PLOS global public health · 2026Article
- Incidence of Neonatal Meningitis and the Premature Mortality in Eastern Sub-saharan Africa, From 1990 to 2023: A Global Burden of Diseases Study.Sage open pediatricsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOptimal strategies to reduce antimicrobial resistance (AMR) and their effect on newborns in low-income and middle-income countries (LMICs) remain unclear. We assessed the effectiveness of AMR mitigation strategies for newborn care in LMICs.
methodsA systematic review and meta-analysis was conducted. We searched MEDLINE, Embase, CINAHL, Global Index Medicus, Cochrane Central Register of Controlled Trials, and grey literature from Jan 1, 2000, to Nov 20, 2025, for randomised or quasi-randomised trials, quasi-experimental studies, observational or implementation studies, and programme evaluations. We included studies comparing any intervention, policy, or strategy designed to mitigate AMR development and spread (intervention) among newborns receiving facility-based or community-based care in LMICs (population), with standard practices or no intervention (comparator), on a range of outcomes including clinical and antibiotic use outcomes (outcome). Strategies to reduce AMR were categorised as regulation (structural or organisational actions), education (health-care worker trainings), or optimisation (responsible antimicrobial use). We pooled data from included studies to estimate the effectiveness of each of the three strategy types or a combination thereof. Given the low-resource context, we also narratively synthesised the available evidence on barriers and facilitators to implementing strategies to reduce AMR in newborn care settings (PROSPERO CRD42023388338).
findingsOf 3688 studies screened, 31 facility-based studies were included. Regulation reduced the risk of newborns receiving at least one antimicrobial by 21% (risk ratio 0·79 [95% CI 0·77-0·80]), but had no effect on neonatal sepsis risk. Optimisation reduced culture-positive sepsis risk by 32% (0·68 [0·55-0·83]) and risk of newborns on antibiotics by 13% (0·87 [0·78-0·98]), but had no effect on neonatal mortality risk. Regulation and optimisation did not significantly reduce neonatal mortality due to nosocomial bloodstream infection (BSI) risk (0·62 [0·31-1·25]). Regulation, education, and optimisation reduced neonatal mortality risk by 27% (0·73 [0·57-0·93]) and multidrug-resistant organism infections or colonisation risk by 29% (0·71 [0·52-0·97]). Regulation, education, and optimisation also decreased the risk of newborns receiving antibiotics by 29% (0·71 [0·61-0·81]) and the risk of duration of antibiotic therapy exceeding 5 days by 64% (0·36 [0·14-0·93]). Effect direction plots revealed overall positive directions of effect for outcomes including neonatal mortality (72·72%), neonatal mortality due to nosocomial BSI (100%), sepsis (75%), and drug-resistant (100%) and multidrug-resistant (80%) infection and colonisation. Effect direction plots also showed decreased overall antibiotic use (94·7%), access (71·4%) and watch (88·9%) antibiotic use, and duration of antibiotic therapy (83·3%) after strategies to reduce AMR were implemented. Common implementation barriers included delays in reporting culture test results, health-care worker non-adherence to infection prevention and control measures, and challenges in antibiotic prescribing for culture-negative newborns with sepsis-like presentation.
interpretationTo improve clinical outcomes, interventions targeting the control of antimicrobials alone will not suffice. Our results showed that three types of interventions (regulation, education, and optimisation) must be taken together to reduce AMR. These results can inform and accelerate guidance development for multi-dimensional, holistic, and integrated maternal and newborn care programmes in LMICs.
fundingThe Bill & Melinda Gates Foundation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.